KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.
about
Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveHybridization-Induced Aggregation Technology for Practical Clinical Testing: KRAS Mutation Detection in Lung and Colorectal Tumors.Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimensA comparability study of 5 commercial KRAS testsKRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment.Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implicationsA multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancersPhospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy.Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective techniqueDecentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay.Optimized Multiplex Detection of 7 KRAS Mutations by Taqman Allele-Specific qPCR.Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective.Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue.KRAS Testing: A Tool for the Implementation of Personalized Medicine.A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas.Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancersOptimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer.Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology.Laboratory methods for KRAS mutation analysis.Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.Whole cancer genome sequencing by next-generation methods.Detection of KRAS and BRAF mutations in advanced colorectal cancer by allele-specific single-base primer extension.Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond.KRAS mutation testing in clinical practice.Quality assurance in clinical trials--the role of pathology.KRAS and BRAF genotyping of synchronous colorectal carcinomas.Automated objective determination of percentage of malignant nuclei for mutation testing.Sensitive detection of KRAS mutations using enhanced-ice-COLD-PCR mutation enrichment and direct sequence identification.Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma.KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance.Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.Analysis of KRAS Mutations of Exon 2 Codons 12 and 13 by SNaPshot Analysis in Comparison to Common DNA Sequencing.SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics.[Digital PCR compartmentalization I. Single-molecule detection of rare mutations].Comparative screening of K-ras mutations in colorectal cancer and lung cancer patients using a novel real-time PCR with ADx-K-ras kit and Sanger DNA sequencing.The usability of allele-specific PCR and reverse-hybridization assays for KRAS genotyping in Serbian colorectal cancer patients.KRAS testing on colo-rectal carcinoma cytological imprints.Integrated ¹⁸F-FDG PET/perfusion CT for the monitoring of neoadjuvant chemoradiotherapy in rectal carcinoma: correlation with histopathology.
P2860
Q28070038-784553DA-7A20-4637-9414-0686357662F7Q30276632-3E3C1227-FC1C-44DE-AC61-2B65450A89C4Q33559365-3AC97516-80E9-4BDF-B8C6-249CD9E920ECQ33888034-EE319B8E-556F-4915-8D21-AE02028C4DEEQ34142761-0C9FD03D-EDCF-461E-8D1E-04DF30163FB7Q34245784-CD834449-BD6E-41FA-811F-84D3559FE089Q35069989-144B874C-6CB8-4A3D-B174-CD64F34DBAB3Q35169256-B4D14CBC-7DEF-4B1A-BD1B-7B2AE42287ECQ35233751-187EAF8B-4145-4C5E-B3C0-C85EDF88F971Q35721438-ED62DA49-30DB-494E-8386-FC3DEBEDB660Q35836711-7A26E6A2-F3CA-4DE8-BD00-60D61324E761Q36134534-71DB0797-E655-476B-BF41-75783BAE8973Q36289392-84F9F8AD-16EC-4E5E-965B-C47B164429E5Q36334470-795F3169-7C8D-4D44-B6AC-409A123A0DF4Q36481945-A56B6448-A627-4575-BD6D-392CA6448E2CQ36523724-540F676E-0112-42F6-878B-76921F12E3B6Q36761405-C487B507-8359-423F-A0FF-BFACAB8BBAF1Q37231968-83A15C77-2886-461A-B048-A80E8C33A907Q37886990-7FE9CD14-FE29-468C-921B-7F30F242B06FQ37899889-82B215B1-4DB6-4D08-8325-EC76F2A504D4Q37916396-1F94EF22-6F4F-4F42-B878-9BD727F81BD0Q37932206-DB7B6EE1-B9DF-4061-9D78-B140B08CF80DQ37948845-D625E28F-53F8-4E95-9E64-47F44AF76C24Q38089481-ED5C72EA-EE01-472B-94C0-A3CBA9FD0E01Q38136134-62AE10DC-85C1-4498-AEC3-0BCCD8D2E70CQ38285393-B8AF887B-3637-44A0-B9E4-F6933BED4BFFQ38596988-B17FA8CB-7C48-4EEC-9F85-85F22BD24BF8Q38932624-A3FE6903-326D-4AFB-83AC-79091AAB2604Q38960732-F3A9A9F6-CE65-4756-841A-D2BFB0A03C6AQ39095680-67B71B40-93D2-4F70-A266-6D700FC18F2DQ39198062-A232BB2B-0E9D-4D34-92F5-7D463DEEF50EQ39225749-A3E526B4-FC7A-4336-A21A-563E3C35EB36Q39757608-1B7E81EF-875B-4F79-8D7F-AC5D29EA0621Q41487628-8A20ECD9-B09B-4D54-8500-F8C966249539Q42075151-A4D0790D-8889-4A16-93A8-E30DDEA0C64EQ44550996-FC25B1F8-FF4C-48C8-B69F-F5AD5CCFE077Q45409586-AA65A883-56AB-4104-938B-CFA61369FE1FQ46700404-24EB247B-24BE-4FA2-A9DC-C5C0B3DB7776Q51812048-157ACF9C-5838-4548-808D-99A1B4C0E402Q53068289-726B1740-63BA-4AF8-95B1-544CE4D3C8B8
P2860
KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
KRAS genotyping of paraffin-em ...... thods and impact of histology.
@en
KRAS genotyping of paraffin-em ...... thods and impact of histology.
@nl
type
label
KRAS genotyping of paraffin-em ...... thods and impact of histology.
@en
KRAS genotyping of paraffin-em ...... thods and impact of histology.
@nl
prefLabel
KRAS genotyping of paraffin-em ...... thods and impact of histology.
@en
KRAS genotyping of paraffin-em ...... thods and impact of histology.
@nl
P2093
P2860
P50
P1476
KRAS genotyping of paraffin-em ...... thods and impact of histology.
@en
P2093
Albrecht Stenzinger
Annika Lehmann
Christiane Schewe
Christine Sers
Jan Budczies
Olfert Landt
Volker Heiser
P2860
P356
10.2353/JMOLDX.2010.090079
P577
2009-12-10T00:00:00Z